Loading the state's markets…
Loading the state's markets…
Loading the market…
Medicare market size, surgeons and outlook to 2030
Medicare fee-for-service peripheral arterial intervention cases in Massachusetts: reported (2020, the pandemic year, left out of the line), then forecast with its 80% range. One year ahead, this procedure’s market forecast has been off by 8% on average (237 state-years, 2020–2024): read it as a direction with a margin.
| Year | Surgeons | Medicare FFS | Advantage share |
|---|---|---|---|
| 2019 | 32 | 4,293 | 28% |
| 2020 | 27 | 4,106 | 30% |
| 2021 | 33 | 3,801 | 32% |
| 2022 | 34 | 3,786 | 35% |
| 2023 | 30 | 3,397 | 38% |
| 2024 | 34 | 3,386 | 39% |
| 2025 from claims | – | 3,700 3,396–3,915 | 40% |
| 2026 forecast | – | 3,810 3,352–4,397 | 39% |
| 2027 forecast | – | 3,871 3,309–4,613 | 40% |
| 2028 forecast | – | 3,933 3,282–4,816 | 40% |
| 2029 forecast | – | 3,996 3,264–5,012 | 40% |
| 2030 forecast | – | 4,060 3,253–5,203 | 40% |
Iliac, femoropopliteal, and tibial angioplasty, stenting, atherectomy. Professional codes (what the surgeon bills): CPT 37220, 37221, 37224, 37225, 37226, 37227, 37228, 37229, 37230, 37231; the hospital bills MS-DRG 252, 253, 254.
Surgeons and fee-for-service cases are from CMS’s Medicare Physician & Other Practitioners files, counted where the surgeon billed; state totals include the cases CMS leaves out of the surgeon-level file (under 11 patients). All Medicare adds patients in Medicare Advantage at the state’s enrollment share; all payers scales Medicare by its share of the procedure nationally. The forecast carries cases per resident 65+ forward with the Census projection of residents 65+. How the numbers are made · Data sources
The 10 busiest do 53% of the cases CMS names in Massachusetts; 19 surgeons do 80% of them.
MedaRep names every one, ranked by volume, with their practice, hospitals, trend, forecast and which device companies already engage with them.
In 2025, 23% inpatient hospital, 35% hospital outpatient, 43% office. The share outside the hospital has moved +26 pts since 2019, so more of this market is decided in surgery centers and offices each year.
| State | Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast |
|---|---|---|---|---|---|---|
| New York | 97 | 12,468−0.1%/yr | −0.1%/yr | 6.5 | 60% | 16,300 in 2030+4.6%/yr |
| New Jersey | 55 | 8,709+2.3%/yr | +2.3%/yr | 8.0 | 77% | 12,700 in 2030+6.4%/yr |
| Pennsylvania | 34 | 4,796−11%/yr | −11%/yr | 3.3 | 15% | 4,870 in 2030+0.3%/yr |
| Connecticut | 14 | 1,650−9%/yr | −9%/yr | 4.7 | 71% | 1,560 in 2030−1%/yr |
| New Hampshire | 5 | 534−11%/yr | −11%/yr | 2.3 | 0% | 1,240 in 2030+15%/yr |
| Rhode Island | 4 | 346−12%/yr | −12%/yr | 3.6 | 54% | 380 in 2030+1.5%/yr |
| Maine | 1 | 250−14%/yr | −14%/yr | 1.5 | 0% | 260 in 2030+0.5%/yr |
| Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast | |
|---|---|---|---|---|---|---|
| Dialysis access | 31 | 2,905−7.2%/yr | −7.2%/yr | 3.20.5× | 22% | 3,070 in 2030+0.9%/yr |
| Superficial venous ablation | 31 | 1,623−5%/yr | −5%/yr | 1.70.5× | 94% | 1,600 in 2030−0.3%/yr |
| Carotid revascularization | 18 | 984−3.3%/yr | −3.3%/yr | 1.01.0× | 0% | 1,170 in 2030+2.9%/yr |
| Thrombectomy, IVC filters & venous stents | 2 | 738−0.4%/yr | −0.4%/yr | 0.80.6× | 9% | 740 in 2030+0.1%/yr |
| Aortic endografts (EVAR/TEVAR) | 1 | 350−5.5%/yr | −5.5%/yr | 0.40.8× | 0% | 390 in 2030+1.8%/yr |
Peripheral arterial intervention in every state, and its device makers · Every procedure market in Massachusetts · Every state · Compare with New York
Cook leads with 27% of company spending on these surgeons in 2025, −5 pts on 2024.
In 2025, 9 companies reported engagement with Massachusetts’s surgeons worth $65K in consulting, speaking, meals and travel tied to these products, about $1,915 per surgeon billing it. Royalties are left out.
FDA, last 12 months: 58 clearances and approvals in the category, 1 recalled product line. A recall is a public FDA notice, not a finding of fault.
Which surgeons each company engages, and the dollars reported, are in the ranking. Open Payments shows the payments companies reported. It suggests engagement, not which devices a surgeon uses, and is not evidence of wrongdoing. Every company in the category.
Share of the cases CMS names by surgeon, by where they billed. Open one for its ranking.